Marks significant milestone for breakthrough biologic to treat rare blood cancers
The Hydrus Microstent stands out as the first and only MIGS device backed by five-year clinical outcomes
The study hit its primary goal, showing a statistically significant rise in participants achieving EASI-75
The FDA decision was based on results from the pivotal POETYK PsA-1 and POETYK PsA-2 Phase 3 trials
Indomo’s ClearPen system combines a proprietary self-injection device and microneedle with a modernized triamcinolone acetonide formulation
The two companies will collaborate to evaluate Hopewell’s ttLNPs for clinical applications
Germany will be the first launch market
Under the deal, Hims & Hers will offer patients access to FDA-approved versions of Ozempic and Wegovy at the same self-pay prices available through other telehealth platforms
Subscribe To Our Newsletter & Stay Updated